IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results

IRADIMED CORPORATION, a leader in developing innovative MRI-compatible medical devices, has released its financial results for the second quarter of 2025. The company reported record revenue and earnings, reflecting strong operational performance and market demand.

Financial Highlights

For the second quarter of 2025, IRADIMED CORPORATION reported a record revenue of $20.4 million, marking a 14% increase compared to the same period in 2024. The company also achieved a record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49, representing increases of 18% and 17%, respectively, from the previous year. Net income for the quarter was $5.8 million, up from $4.9 million in the same period of 2024.

Business and Operational Highlights

The company continues to see strong demand for its MRI-compatible medical devices. Sales of MRI Compatible IV Infusion Pump Systems and MRI Compatible Patient Vital Signs Monitoring Systems contributed significantly to the revenue growth. Domestic sales accounted for 89% of total revenue for the quarter. The gross profit margin remained steady at 78%.

Strategic Initiatives and Corporate Developments

IRADIMED CORPORATION declared a regular quarterly cash dividend of $0.17 per share, payable on August 28, 2025. The company also completed the construction of its new facility in Orlando, Florida, which is expected to enhance operational capacity and support future growth.

Management's Perspective

Roger Susi, President and CEO of IRADIMED, expressed pride in the company's sixteenth consecutive quarter of record revenue. He highlighted the company's focus on operational excellence and the anticipated benefits of the new facility. Susi also mentioned the upcoming commercialization of the next-generation MRI-compatible IV infusion pump, expected to drive sustained growth.

Future Outlook

For the third quarter of 2025, IRADIMED CORPORATION expects revenue between $20.5 million and $20.9 million, with GAAP diluted EPS ranging from $0.41 to $0.45 and non-GAAP diluted EPS from $0.45 to $0.49. The company has raised its full-year 2025 revenue guidance to $80.0 million to $82.5 million, with GAAP diluted EPS projected at $1.60 to $1.70 and non-GAAP diluted EPS at $1.76 to $1.86.

SEC Filing: IRADIMED CORP [ IRMD ] - 8-K - Aug. 01, 2025